Pathologic Dilatation (Ectasia)

Subscribe to Selected New Research on Pathologic Dilatation

558 relevant articles (21 outcomes, 23 trials/studies) found for this Disease

Description: The condition of an anatomical structure's being dilated beyond normal dimensions.

Also Known As:

Ectasia; Dilatation, Pathologic; Dilatation, Pathological; Dilatations, Pathologic; Dilatations, Pathological; Pathologic Dilatations; Pathological Dilatation; Pathological Dilatations

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions

Anatomical Pathological Conditions

Pathologic Dilatation: 558

Related Diseases

1.	Hemorrhage
2.	Keratoconus
3.	Aneurysm (Aneurysms)
4.	Myopia
5.	Fibrosis (Cirrhosis)
172 Diseases and 302 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Randleman, J Bradley: 10 articles (05/2008 - 02/2003)
2.	Stulting, R Doyle: 10 articles (05/2008 - 02/2003)
3.	Binder, Perry S: 6 articles (09/2007 - 12/2003)
4.	Kymionis, George D: 5 articles (12/2007 - 01/2002)
5.	Turhan, Hasan: 4 articles (05/2007 - 11/2004)
6.	Yetkin, Ertan: 4 articles (05/2007 - 11/2004)
7.	Mohammadpour, Mehrdad: 3 articles (07/2008 - 10/2007)
8.	Dogan, Abdullah: 3 articles (05/2008 - 07/2003)
9.	Pallikaris, Aristofanis I: 3 articles (12/2007 - 11/2006)
10.	Aksoy, Yuksel: 3 articles (05/2007 - 02/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pathologic Dilatation:

1.	glucuronyl glucosamine glycan sulfate (Vessel)IBA 09/01/2007 - "According to the angiographic definition used in the Coronary Artery Surgery Study, a vessel is considered to be ectasic when its diameter is > or = 1.5 times that of the adjacent normal segment in segmental ectasia" 02/01/2005 - "According to the angiographic definition used in the Coronary Artery Surgery Study, a vessel is considered to be ectasic when its diameter is > or =1.5 times that of the adjacent normal segment in segmental ectasia" 05/01/2007 - "The right coronary artery was most commonly affected with ectasia (50%) and most participants had single-vessel involvement (74%)" 09/01/2005 - "According to the ectasia ratio, ectatic vessels were divided into two groups: ectasias with a 1.5- to 2.0-fold increase (group A) and more than 2.0-fold increase (group B) in normal vessel diameter" 04/01/2005 - "However, subgroup analysis demonstrated that MMP-3 level is significantly lower in patients with generalized CEs compared to those with single vessel ectasia" Get all the results and reference details, order at left...
2.	ElastinIBA 03/23/2004 - "MMP-9 or MMP-12 deficiency conferred significant protection against transmedial elastin degradation and ectasia in the atherosclerotic media" 06/30/1999 - "at 50 mg/kg) had no effect on the extent of aortic atherosclerosis (36 +/- 4% versus 30 +/- 2% in controls), but both aortic medial elastin destruction and ectasia grade were significantly reduced (38% and 36%, respectively, p < 0.05)" 07/16/1982 - "These findings point to a change in the structure or metabolism of elastin in the aortic wall in the Marfan syndrome and at least in some other patients with annulo-aortic ectasia." 11/15/1985 - "Aortic samples from patients with annulo-aortic ectasia (aneurysm of the ascending aorta), including one with classical Marfan syndrome, contained less elastin (CNBr-insoluble material) than did the age-matched controls" 01/01/2007 - "The elastic lamellae undergo fragmentation and thinning, leading to ectasia and a gradual transfer of mechanical load to collagen, which is 100-1000 times stiffer than elastin" Get all the results and reference details, order at left...
3.	ArgonIBA 09/01/2008 - "The beneficial effects of argon plasma coagulation in the management of different types of gastric vascular ectasia lesions in patients admitted for GI hemorrhage." 06/01/2004 - "GI stromal tumor unmasked by argon plasma coagulation of vascular ectasia." 10/14/2007 - "Duodenal vascular ectasia may be a cause of upper gastrointestinal bleeding in patients with cirrhosis, and argon plasma coagulation may be effective and safe to achieve hemostasis of this lesion." 02/01/2008 - "Bleeding gastric vascular ectasia treated by argon plasma coagulation: a comparison between patients with and without cirrhosis." 07/01/1982 - "The blue-green light from this laser has been found to be particularly useful in treating red-blue vascular lesions and is now the therapy of choice for port-wine stains and several types of small vascular ectasia; adenoma sebaceum characterized by prominent vascular ectasia also respond extremely well to argon laser radiation." Get all the results and reference details, order at left...
4.	Mitomycin (Mitomycin-C)FDA LinkGeneric 05/01/1999 - "Corneal ectasia after trabeculectomy with mitomycin C application." 01/01/2006 - "Adjunctive utilization of intraoperative low-dose 0.02% mitomycin C for the management of chronic uveitic glaucoma patients who are under concomitant systemic immunosuppressive regimen may enhance the risk of subacute postoperative sclerolimbal ectasia" 01/01/2006 - "A case of early-onset sclerolimbal ectasia following low-dose topical mitomycin C application during uveitic glaucoma surgery is reported" Get all the results and reference details, order at left...
5.	Estrogens (Estrogen)FDA Link 04/15/1989 - "Estrogen therapy in digestive hemorrhage caused by diffuse vascular ectasia of the gastric antrum]" 12/01/2005 - "Urgent aortic valve replacement (AVR) was performed after preoperative hormonal (estrogen-progesterone) therapy, that might be effective for bleeding from vascular ectasia" Get all the results and reference details, order at left...
6.	ThiazidesIBA 05/01/1978 - "3) Thiazides are effective in normocalciuric as well as hypercalciuric patients and in most patients with tubular ectasia (medullary sponge kidney)" Get all the results and reference details, order at left...
7.	Progesterone FDA LinkGeneric 12/01/2005 - "Urgent aortic valve replacement (AVR) was performed after preoperative hormonal (estrogen-progesterone) therapy, that might be effective for bleeding from vascular ectasia" Get all the results and reference details, order at left...
8.	Phenobarbital (Luminal)FDA Link 08/01/2007 - "Coronary artery ectasia was defined as without any stenotic lesion, on visual assessment, of the coronary arteries with a luminal dilatation 1.5-fold or more of the adjacent normal coronary segments" 06/01/2007 - "Coronary artery ectasia (CAE) is defined as a localized or diffuse non-obstructive lesion of the epicardial coronary arteries with a luminal dilation exceeding 1.5-fold the diameter of the normal adjacent arterial segment" 01/01/2004 - "Coronary artery ectasia was defined as nonobstructive lesions of the coronary arteries with a luminal dilatation 1.5-fold or more of the adjacent normal coronary segments" 01/01/1987 - "The study of the first local excision leads to the thought of a "duct ectasia with a luminal benign papilloma"" 06/01/1997 - "However, the lesions differed from SCLE by virtue of vasculopathic alterations comprising vascular ectasia, hypovascularity, and/or luminal thrombosis confined to the superficial vascular plexus and a sclerodermoid tissue reaction, the latter seen in two cases" Get all the results and reference details, order at left...
9.	Matrix MetalloproteinasesIBA 12/01/2008 - "Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia." 04/01/2005 - "We hypothesized that dysregulation of circulating matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) contributes to ectasia formation" 12/01/1999 - "Coronary ectasia in familial hypercholesterolemia: histopathologic study regarding matrix metalloproteinases." 03/23/2004 - "In addition, deficiency of MMP-9 or MMP-12 protected apolipoprotein E-deficient mice against atherosclerotic media destruction and ectasia, mechanisms that implicate the involvement of these MMPs in aneurysm formation." Get all the results and reference details, order at left...
10.	tebufenozide (Mimic)IBA 02/01/2005 - "CONCLUSIONS: These morphologic findings in the Marfan phenotype mouse mimic the findings of disordered elastic-fibers in other Marfan tissues and demonstrate gross attenuation of the tissue architecture, corroborating the theory that dural ectasia in Marfan syndrome results from hydrostatic pressure on weakened dura" 02/01/1995 - "Mammographic appearances of mammary duct ectasia that mimic carcinoma in a screening programme." 02/01/1995 - "The aim of this study is to demonstrate the spectrum of mammographic appearances of mammary duct ectasia that mimic carcinoma in a breast cancer screening programme" 02/01/2000 - "A rare variant of pancreatic ductal adenocarcinoma referred to as "large-duct-type" is characterized by microcystic ectasia of the invasive glands and may mimic other cystic tumors at the microscopic level" Get all the results and reference details, order at left...
179 Drugs and Important Bio-Agents and 263 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Laser In Situ Keratomileusis (LASIK) 03/01/2003 - "CONCLUSIONS: Intracorneal ring segments implantation improved uncorrected visual acuity and best spectacle-corrected visual acuity in patients with post-LASIK ectasia" 05/01/2008 - "CONCLUSIONS: The Ectasia Risk Score System is a valid and effective method for detecting eyes at risk for ectasia after LASIK and represents a significant improvement over previously utilized screening strategies." 01/01/2008 - "CONCLUSIONS: A quantitative method can be used to identify eyes at risk for developing ectasia after LASIK that, if validated, represents a significant improvement over current screening strategies." 09/01/2002 - "When used in combination with videokeratography, the Orbscan II topography system may be helpful in identifying patients who are potentially at high risk for developing ectasia after LASIK." 01/01/2002 - "CONCLUSION: Implantation of INTACS in eyes with corneal ectasia after LASIK resulted in good refractive outcome, absence of complications, and improvement in visual acuity." Get all the results and reference details, order at left...
2.	Penetrating Keratoplasty 03/01/2007 - "Penetrating keratoplasty versus intrastromal corneal ring segments to correct bilateral corneal ectasia: preliminary study." 07/01/2007 - "SUMMARY: These new forms of surgery are viable alternatives to conventional penetrating keratoplasty and bring added safety profiles for long-term visual rehabilitation and restoration of tectonic integrity in central and peripheral forms of corneal ectasia." 03/01/2007 - "PURPOSE: To describe the outcomes over time in patients with corneal ectasia pathology treated with intrastromal corneal ring segments (Intacs, Addition Technology, Inc.) in 1 eye and penetrating keratoplasty (PKP) in the other eye" 09/01/2002 - "In the short term, these techniques seem to be helpful in reducing the progression of corneal ectasia after excimer laser surgery, delaying or avoiding the need of penetrating keratoplasty." 09/01/2008 - "Penetrating keratoplasty for corneal ectasia after laser in situ keratomileusis." Get all the results and reference details, order at left...
3.	Transplants (Transplant) 09/01/2006 - "The suturing of a corneoscleral graft over a severely ectatic cornea may be an acceptable technique for providing tectonic tissue support and stabilizing eyes with severe anterior segment ectasia." 09/01/2006 - "Three months postoperatively, the graft was stable with no progression of the ectasia" 10/01/2003 - "METHODS: Fourteen Marfan patients who received composite graft replacement for annuloaortic ectasia with or without aortic dissection required late reoperation thorough re-median sternotomy" 04/01/2003 - "Common iliac artery ectasia and aneurysmal disease has become another indication for use of the AneuRx commercial graft at our institution, with no significant differences in intermediate outcome" 02/01/1998 - "A 31-year-old man with type A chronic aortic dissection associated with annuloaortic ectasia underwent the concomitant graft replacement of the total aortic root and the transverse aortic arch" Get all the results and reference details, order at left...
4.	Excimer Lasers 09/01/2002 - "In the short term, these techniques seem to be helpful in reducing the progression of corneal ectasia after excimer laser surgery, delaying or avoiding the need of penetrating keratoplasty." 01/01/2008 - "PURPOSE: To analyze the epidemiologic features of ectasia after excimer laser corneal refractive surgery, to identify risk factors for its development, and to devise a screening strategy to minimize its occurrence" 08/01/2006 - "PURPOSE: To describe the clinical and ultrastructural features of a prominent ectasia of the cornea that occurred 9 years after excimer laser photorefractive keratectomy (PRK)" 01/01/2008 - "PARTICIPANTS: All cases of ectasia after excimer laser corneal refractive surgery published in the English language with adequate information available through December 2005, unpublished cases seeking treatment at the authors' institution from 1998 through 2005, and a contemporaneous control group who underwent uneventful LASIK and experienced a normal postoperative course" 08/01/2006 - "PURPOSE: To evaluate excimer laser-assisted anterior lamellar keratoplasty to augment thin corneas as in keratoconus (<350 microm) and corneal ectasia after laser in situ keratomileusis (LASIK) and to treat anterior stromal opacities" Get all the results and reference details, order at left...
5.	Aftercare (After-Treatment) 02/01/2000 - "After treatment, visual acuity temporarily improved but was followed by visual impairment, with corneal ectasia detected by topography" 12/01/1985 - "The Nd YAG laser appears to produce better long term results as its greater penetration makes it possible to ablate the main areas of vascular ectasia in the submucosa, although it does have a slightly higher risk of causing haemorrhage in the first few days after treatment." 03/17/1989 - "In 108 patients with nonpuerperal mastitis (inflammatory symptoms of duct ectasia), serum prolactin levels were determined before, during, and after treatment" Get all the results and reference details, order at left...
82 Therapies and Procedures and 325 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician
Research Summary Report
on Pathologic Dilatation

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 21 Outcomes
Top 179 Key Medications
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>